Skip to main content

Dr. Terrence J. Bradley, MD

Hematology (Hematology (Internal Medicine) Physician)

  • Medicare participating

At a glance

Years since graduation
14
In the NPI registry since
2012
Medicare patients seen, 2024
90

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2012Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology (Internal Medicine) Physician primary
    FL license ME137418
  • Internal Medicine Physician
    NY license 272574

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
90
Services billed
423
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes23959
Established patient office or other outpatient visit, 40-54 minutes13039
Established patient office or other outpatient visit, 20-29 minutes2713

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Venclexta (venetoclax)40
Inqovi (decitabine/cedazuridine)28
Jakafi (ruxolitinib phosphate)20
Hydroxyurea
Other prescribers in Miami, FL
20
Acyclovir
Other prescribers in Miami, FL
15
Ondansetron Hcl
Other prescribers in Miami, FL
14
Inrebic (fedratinib dihydrochloride)13
Idhifa (enasidenib mesylate)13
Ojjaara (momelotinib dihydrochloride)13
Vonjo (pacritinib citrate)12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 6 companies reported 9 payments worth $5,120 in total to this clinician.

By company
Sanofi US Services Inc.$2,514
Novartis Pharmaceuticals Corporation$1,780
Daiichi Sankyo Inc.$650
Rigel Pharmaceuticals, Inc.$124
Pfizer Inc.$28.89
Celgene Corporation$23.89
By type
Consulting Fee$4,732
Food and Beverage$388

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 14, 2025Sanofi US Services Inc.
Nov 14, 2025
Consulting Fee
AYVAKIT · Gastroenterology
$2,332
Jul 11, 2025Novartis Pharmaceuticals Corporation
Jul 11, 2025
Consulting Fee
SCEMBLIX · Oncology
$1,750
Sep 22, 2025Daiichi Sankyo Inc.
Sep 22, 2025
Consulting Fee
Vanflyta · ONCOLOGY
$650

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $148,255 in research payments for these studies, mostly to the institutions running them.

  • A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms
    Incyte Corporation
  • A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
    Sumitomo Pharma America, Inc. · Recruiting · NCT04176198
  • An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis
    Geron Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology clinicians in Miami

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 1, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1134495021. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.